

**IN THE CLAIMS**

This listing of the claims replaces all prior versions of the claims in the application. Note that claims 30, 33, and 35 have been newly canceled, without prejudice or disclaimer.

1. (Previously Presented) An isolated polypeptide selected from the group consisting of:
  - a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2,
  - b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2,
  - c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, and
  - d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.

2.-10. (Canceled)

11. (Currently Amended) An isolated antibody which specifically binds to a polypeptide selected from the group consisting of:
  - a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2,
  - b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2,  
and
  - c) ~~a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, and~~

~~[[d]] a polypeptide comprising an immunogenic fragment of a polypeptide having consisting of~~  
an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.

12. (Previously Presented) An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4,
- b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4,
- c) a polynucleotide complementary to a polynucleotide of a),
- d) a polynucleotide complementary to a polynucleotide of b), and
- e) an RNA equivalent of a)-d).

13.-30. (Canceled)

31. (Original) The antibody of claim 11, wherein the antibody is:

- a) a chimeric antibody,
- b) a single chain antibody,
- c) a Fab fragment,
- d) a F(ab')<sub>2</sub> fragment, or
- e) a humanized antibody.

32. (Original) A composition comprising an antibody of claim 11 and an acceptable excipient.

33. (Canceled)

34. (Original) A composition of claim 32, wherein the antibody is labeled.

35. (Canceled)

36. (Previously Presented) A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibodies from said animal, and
- c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.

37. (Original) A polyclonal antibody produced by a method of claim 36.

38. (Original) A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.

39. (Previously Presented) A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibody producing cells from the animal,
- c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells,
- d) culturing the hybridoma cells, and
- e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.

40. (Original) A monoclonal antibody produced by a method of claim 39.

41. (Original) A composition comprising the monoclonal antibody of claim 40 and a suitable carrier.

42. (Original) The antibody of claim 11, wherein the antibody is produced by screening a Fab expression library.

43. (Original) The antibody of claim 11, wherein the antibody is produced by screening a recombinant immunoglobulin library.

44. (Previously Presented) A method of detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2 in a sample, the method comprising:

a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and

b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2 in the sample.

45. (Previously Presented) A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2 from a sample, the method comprising:

a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and

b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.

46.-55. (Canceled)

56. (Original) A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

57.-59. (Canceled)

60. (New) An isolated antibody of claim 11, which specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:1.

61. (New) An isolated antibody of claim 11, which specifically binds to a polypeptide selected from the group consisting of:

- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:1, and
- b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1.

62. (New) An isolated antibody of claim 11, which specifically binds to a polypeptide selected from the group consisting of:

- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:1, and
- b) a polypeptide comprising an immunogenic fragment of a polypeptide consisting of the amino acid sequence of SEQ ID NO:1.